Materials and methods Retrospective review of patients treated with pamidronate from January 1995 to June 2006 in Sant Joan de Déu hospital (Spain). Patients:younger than 18 years that underwent treatment with the protocol for at least one year and with z-score < -2.5, fractures and z-score < -1 or documented bone pain with z-score < -1. They were classified into 4 groups: osteogenesis imperfec...

OBJECTIVE Optimized production and quality control of ytterbium-175 (Yb-175) labeled pamidronate and alendronate complexes as efficient agents for bone pain palliation has been presented. METHODS Yb-175 labeled pamidronate and alendronate (175Yb-PMD and 175Yb-ALN) complexes were prepared successfully at optimized conditions with acceptable radiochemical purity, stability and significant hydro...

We have examined the deterioration of implant fixation after withdrawal of parathyroid hormone (PTH) in rats. First, the pull-out force for stainless-steel screws in the proximal tibia was measured at different times after withdrawal. The stimulatory effect of PTH on fixation was lost after 16 days. We then studied whether bisphosphonates could block this withdrawal effect. Mechanical and histo...

Conclusion Despite a lower increase in z-score in our serie, the clinical efficacy is similar to other protocols. There is a tendency towards greater gain in Z-score as the annual dosage increases. References 1. Glorieux FH, et al.: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. The New England Journal of Medicine 1998, 339:947-52. 2. Arikoski P, et al.: I...

Bisphosphonates are potent inhibitors of bone resorption. There are marked differences in their antiresorptive potency based on the structure of their side chains. Recent large double-blind, placebo-controlled studies have shown the benefit of monthly intravenous pamidronate (Aredia) in reducing skeletal complications among patients with osteolytic bone metastases from breast cancer or multiple...

The adverse events of the nitrogen-containing bisphosphonates are reviewed. Oral bisphosphonates (alendronate, risedronate and ibandronate), mainly used for the treatment of osteoporosis, have been associated with adverse events from the upper gastrointestinal tract, acute phase response, hypocalcaemia and secondary hyperparathyroidism, musculoskeletal pain, osteonecrosis of the jaw and ocular ...